Skip to main content
BBIO
NASDAQ Life Sciences

Acoramidis Shows First-Ever Reversal of Cardiac Disease Progression in ATTR-CM

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$76.69
Mkt Cap
$14.975B
52W Low
$48.78
52W High
$93.415
52W Position info
57% above low
Off High info
18% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

BBIO sits 57% above its 52-week low of $48.78.

Summary

BridgeBio presented new Phase 3 ATTRibute-CM data at ESC Congress 2026 showing acoramidis (Attruby) is the first therapy to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging. In a completer analysis, 54% of acoramidis-treated patients showed clinically meaningful improvement in LV systolic function at Month 30 versus 20% on placebo, and 53% of continuous-acoramidis patients at Month 42. Patients also gained 65 additional days alive and out of hospital by Month 36 versus placebo. Month 54 OLE data in variant ATTR-CM showed all-cause mortality of 30.4% with continuous acoramidis versus 66.7% with placebo-to-acoramidis in the p.Val142Ile subgroup. These data strengthen the differentiation of acoramidis in a competitive ATTR-CM market and support the recently initiated ASCEND-ATTR Phase 3b/4 study. Additional data will be presented at HFSA 2026 in October.

At the time of this announcement, BBIO was trading at $76.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $76.03 info
Change: +$5.34 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $76.03 info
Change: +$4.59 (+6%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $76.03 info
Change: +$5.36 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $76.03 info
Change: +$10.28 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info